ACE-083 is a protein construct based on follistatin fused to an Fc fragment. Its main idea is not so much what it does as where: the molecule was designed to act mostly at the injection site rather than throughout the body. Here is why that matters and what the studies showed.

What ACE-083 is, briefly

ACE-083 is a follistatin-Fc, a so-called ligand trap. Follistatin binds myostatin and other family members that restrain muscle growth through the ActRII receptors. By sequestering those ligands locally, the construct releases the brake in the specific muscle group it was injected into. The mechanistic detail is in the ACE-083 monograph.

What the studies showed

A 2019 preclinical paper showed that the follistatin trap ACE-083 induces localized muscle hypertrophy at the site of administration (Scientific Reports, 2019). That was the whole point of the construct: a targeted rather than a systemic effect.

The project then reached the clinic. A randomized phase 2 study tested ACE-083 in patients with facioscapulohumeral muscular dystrophy (Muscle & Nerve, 2022). Here an honest detail matters: although the agent increased muscle volume, the study did not show a matching functional improvement, and development was later halted. It is a useful example that "more muscle" and "better function" are not the same thing.

Why researchers find it interesting

ACE-083 is a convenient model for studying local versus systemic intervention in ActRII signalling. It lets you compare how tissue responds to lifting the myostatin brake in one place, and at the same time it is a reminder that volume and strength are different endpoints.

Research status

Longeva material is research use only. It is not a medicine or a supplement. ACE-083 has no approved indications; the data above concern preclinical and clinical-research work, not a ready treatment, and are not a basis for self-administration.

See also: trial results for ACE-083 where muscle volume did not deliver function.

Lots come with a certificate of analysis from an independent third-party laboratory; a COA (certificate of analysis) by lot number is in the open archive. For presentation and specifications, see the ACE-083 catalogue page.